IPCALAB logo

Ipca Laboratories Limited Stock Price

NSEI:IPCALAB Community·₹386.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author

IPCALAB Share Price Performance

₹1,524.40
108.60 (7.67%)
₹1,415.37
Fair Value
₹1,524.40
108.60 (7.67%)
7.7% overvalued intrinsic discount
₹1,415.37
Fair Value
Price ₹1,524.40
AnalystLowTarget ₹1,415.37
AnalystHighTarget ₹1,731.00
AnalystConsensusTarget ₹1,655.33

IPCALAB Community Narratives

·
Fair Value ₹1.42k 7.7% overvalued intrinsic discount

Rising Regulations And Cost Pressures Will Limit Pharma Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value ₹1.73k 11.9% undervalued intrinsic discount

Emerging Markets In Asia And Africa Will Fuel Healthcare Demand

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value ₹1.66k 7.9% undervalued intrinsic discount

Domestic Chronic Focus And API Capacity Will Foster Global Opportunities

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
₹1.42k
7.7% overvalued intrinsic discount
Revenue
10.6% p.a.
Profit Margin
15.27%
Future PE
33.26x
Price in 2029
₹2.01k
₹1.66k
7.9% undervalued intrinsic discount
Revenue
10.9% p.a.
Profit Margin
15.3%
Future PE
38.48x
Price in 2029
₹2.35k
₹1.73k
11.9% undervalued intrinsic discount
Revenue
12.65% p.a.
Profit Margin
15.8%
Future PE
21.6x
Price in 2029
₹2.48k

Trending Discussion

Updated Narratives

IPCALAB logo

IPCALAB: Upcoming Results And Dividend Decision Will Shape Earnings Visibility

Fair Value: ₹1.42k 7.7% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
IPCALAB logo

IPCALAB: Upcoming Unaudited Results Will Support Bullish View On Steady Fair Value

Fair Value: ₹1.66k 7.9% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
IPCALAB logo

IPCALAB: Firmer Margins And Tighter P E Will Support Future Upside Potential

Fair Value: ₹1.73k 11.9% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet with proven track record.

0 Risks
2 Rewards

Ipca Laboratories Limited Key Details

₹98.2b

Revenue

₹28.2b

Cost of Revenue

₹70.0b

Gross Profit

₹58.6b

Other Expenses

₹11.4b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jun 01, 2026
44.98
71.26%
11.62%
7.4%
View Full Analysis

About IPCALAB

Founded
1949
Employees
16778
CEO
Pranay Godha
WebsiteView website
www.ipca.com

Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.

Recent IPCALAB News & Updates

Narrative Update May 06

IPCALAB: Upcoming Results And Dividend Decision Will Shape Earnings Visibility

Analysts have nudged their fair value estimate for Ipca Laboratories slightly higher from ₹1,406.78 to ₹1,415.37, reflecting updated assumptions around revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled for May 29, 2026 to review standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026 (company filing).

Recent updates

No updates